STOCK TITAN

Johnson & Johnson - JNJ STOCK NEWS

Welcome to our dedicated news page for Johnson & Johnson (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Johnson & Johnson's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Johnson & Johnson's position in the market.

Rhea-AI Summary
Johnson & Johnson (JNJ) will participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) with Joaquin Duato, Chairman and CEO, representing the Company. The live audio webcast will be available to investors on May 29th, at 1:30 pm Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences
-
Rhea-AI Summary
Johnson & Johnson (JNJ) announces its 62nd consecutive year of dividend increase, raising the quarterly dividend by 4.2% to $1.24 per share. This marks a significant milestone for the company, with the annual dividend now at $4.96 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
dividends
-
Rhea-AI Summary
Johnson & Johnson (JNJ) reported a 2.3% sales growth to $21.4 billion in Q1 2024, with adjusted EPS increasing by 12.4%. The company raised its full-year operational sales and adjusted EPS guidance. Operational sales for Innovative Medicine and MedTech segments showed positive growth. Notable products driving growth include DARZALEX, ERLEADA, and CARVYKTI in Oncology, and electrophysiology products in MedTech.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
Rhea-AI Summary
Johnson & Johnson reported a 2.3% sales growth to $21.4 billion in Q1 2024, with operational growth of 3.9% and adjusted EPS increase of 12.4%. The company raised its Full-Year 2024 operational sales and adjusted EPS guidance. Innovative Medicine and MedTech segments showed positive growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
-
Rhea-AI Summary
Johnson & Johnson (JNJ) to participate in the 2024 RBC Capital Markets Global Healthcare Conference on May 15th, with Tim Schmid representing the company. The live webcast will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences
-
Rhea-AI Summary
Johnson & Johnson (JNJ) receives FDA approval for CARVYKTI® for the treatment of relapsed or refractory multiple myeloma, offering patients a potential treatment-free period as early as first relapse. The approval is based on positive results from the Phase 3 CARTITUDE-4 study, showing a 59% reduction in the risk of disease progression or death compared to standard therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
Rhea-AI Summary
Johnson & Johnson (JNJ) to acquire Shockwave Medical, Inc. (SWAV) for $13.1 billion, enhancing its position in cardiovascular intervention. The acquisition aims to drive sales growth, improve patient outcomes, and accelerate operating margin. Shockwave's IVL technology for calcified CAD and PAD treatment aligns with JNJ's focus on cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
-
Rhea-AI Summary
Johnson & Johnson (JNJ) received an unsolicited mini-tender offer from TRC Capital Investment to purchase up to 1 million shares at $151.23 per share, 4.12% lower than the previous closing price. JNJ advises shareholders not to tender their shares due to the offer being below market price and subject to conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
-
Rhea-AI Summary
Johnson & Johnson (JNJ) will participate in the BofA Securities Health Care Conference with John Reed representing the company. The live audio webcast will be available for investors on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
Rhea-AI Summary
Johnson & Johnson (JNJ) will host a conference call to review first-quarter results, featuring top executives. Investors can access the webcast and presentation material on the company's website. The press release provides details on accessing the call and future earnings calls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences earnings
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Stock Data

355.49B
2.40B
0.09%
71.24%
0.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New Brunswick

About JNJ

Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.